Name: Ac-[Tyr1,D-Arg2]-GRF(1-29) Amide: Stable GH Release Peptide
Availability: InStock
Rating: 4.5 (89 reviews)

Ac-[Tyr1,D-Arg2]-GRF (1-29) amide (human) COS NO.93942-91-7

Ac-[Tyr1,D-Arg2]-GRF (1-29) amide (human) (CAS NO. 93942-91-7) is a modified 29-amino-acid peptide with the molecular formula C₁₅₄H₂₅₅N₄₇O₄₃S and molecular weight 3485.1 g/mol. Engineered with N-terminal acetylation (Ac-Tyr¹) and D-arginine substitution (D-Arg²), it is a highly stable, potent agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), designed for robust growth hormone (GH) release studies and preclinical drug development.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Ac-[Tyr1,D-Arg2]-GRF (1-29) amide (human)
CAS NO.	93942-91-7
Appearance	White to off-white lyophilized powder
Molecular Formula	C₁₅₄H₂₅₅N₄₇O₄₃S
Molecular Weight	3485.1 g/mol
Purity (RP-HPLC)	≥ 98.0%
Solubility	Soluble in neutral aqueous buffers (e.g., PBS, Tris-HCl pH 7.4); partially soluble in urea or guanidine hydrochloride (for denatured studies)
Endotoxin	< 1.0 EU/mg
Biological Activity	Modified human GRF (1-29) amide with N-terminal acetylation (Ac-Tyr¹) and D-arginine substitution (D-Arg²). Acts as a potent, stable agonist of the growth hormone secretagogue receptor 1a (GHS-R1a; human, EC₅₀: 0.05–0.5 nM). Enhanced resistance to proteases and improved receptor binding compared to native GRF (1-29). Stimulates growth hormone (GH) release from the anterior pituitary.
Storage Conditions	Store at -20°C in a tightly sealed, light-protected container; avoid moisture and repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

GHS-R1a Activation: Binds to the growth hormone secretagogue receptor 1a (GHS-R1a) with high affinity (human, EC₅₀: 0.05–0.5 nM), triggering Gq/11 protein-coupled signaling cascades.

Enhanced Stability: N-terminal acetylation (Ac-Tyr¹) and D-Arg² substitution resist proteolytic degradation, extending half-life in biological fluids compared to native GRF (1-29).

GH Secretion: Stimulates growth hormone release from the anterior pituitary via GHS-R1a-mediated Ca²⁺ influx and cAMP elevation, bypassing hypothalamic somatostatin inhibition.

2.PRODUCT INDICATIONS

Endocrinology Research: Studying GH regulation, puberty, aging-related hormonal changes, and GH deficiency disorders.

Preclinical Drug Development: Screening GHS-R1a agonists/antagonists for treating growth disorders (e.g., dwarfism) or metabolic diseases (e.g., cachexia).

Long-Term In Vivo Studies: Investigating sustained GH secretion in animal models, leveraging the peptide’s enhanced stability.

3.CLINICAL EFFICACY OF PRODUCT

GH Secretion: In human pituitary cell cultures, it increased GH release by 6–12x (1 nM concentration) vs. baseline, outperforming native GRF (1-29) by 20–30%.

Linear Growth: In GH-deficient rodent models, it promoted 40–60% greater body length increase over 8 weeks vs. untreated controls, with 15–25% higher efficacy than unmodified GRF.

Stability in Vivo: In rat plasma, it retained 80% of initial activity after 24 hours (vs. 30% for native GRF), enabling longer-duration studies.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.